New Genes

New Genes (Beijing) Technology Co., Ltd., commonly known as NGGT, is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of adeno-associated virus (AAV) mediated gene therapies. The company focuses on treating rare genetic disorders and chronic diseases, with a pipeline that includes candidates for Hemophilia A, Phenylketonuria (PKU), Parkinson's disease, and wet age-related macular degeneration. Its lead programs, NGGT-001 and NGGT-002, have entered clinical trials, demonstrating the company's capability in translating genetic research into therapeutic applications. NGGT leverages a proprietary AAV vector platform to optimize gene delivery and expression, aiming to provide one-time curative treatments for patients with high unmet medical needs. The company is supported by prominent venture capital firms and is a key player in the Chinese gene therapy landscape.